Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on February 19, 2016, reporting an event that occurred on February 10, 2016. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a specific executive compensation payment.
Material Changes
On February 10, 2016, the Board of Directors approved a discretionary cash bonus of $175,000 for Howard B. Rosen, the Company's interim Chief Executive Officer, in recognition of his 2015 performance.
Guidance, Outlook, and Management Commentary
The filing notes that as an interim Chief Executive Officer, Mr. Rosen is not eligible for any additional bonus under the Company's 2015 or 2016 cash bonus plans. No other guidance, outlook, risks, or contingencies are discussed in this report.
Investor Verification Checklist
- Verify the total compensation package for the interim CEO beyond this discretionary bonus.
- Confirm the status of the search for a permanent Chief Executive Officer.
- Review the Company's 2015 Annual Report (10-K) for broader financial performance context.